DOCSLIB.ORG

Enfermedades Infecciosas Y Microbiología Clínica Enfermedades Infecciosas Y

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Enfermedades Infecciosas Y Microbiología Clínica Enfermedades Infecciosas Y ISSN: 0213-005X Factor de impacto 2016: 1.714 Enfermedades Infecciosas y Microbiología Clínica Enfermedades Infecciosas y Microbiología Clínica Volumen 37, Especial Congreso 3, Diciembre 2019 Publicación mensual PUBLICACIÓN OFICIAL DE LA SOCIEDAD ESPAÑOLA DE ENFERMEDADES INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA XI Congreso Nacional GeSIDA Diciembre 2019. Volumen 37. Especial Congreso 3. Páginas 1-146 y XIII Reunión Docente de la Red de Investigación de Sida (RIS) Toledo, 10-13 de diciembre de 2019 Incluida en: Index Medicus/MEDLINE Excerpta Medica/EMBASE Current Contents/Clinical Medicine ISI Alerting Services Science Citation Index-Expanded Journal Citation Reports Scopus/MEDES www.elsevier.es/eimc 00 PORTADA_GESIDA 2019.indd 1 26/11/19 14:07 PUBLICACIÓN OFICIAL DE LA SOCIEDAD ESPAÑOLA DE ENFERMEDADES INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA Fundadores Editor Editores Asociados Agustí Pumarola Busquets † Benito Almirante Gragera (Barcelona) Juan Ignacio Alós Cortés (Madrid) Juan García San Miguel † José Ramón Arribas López (Madrid) Emilia Cercenado Mansilla (Madrid) Consejo Editorial Echevarria Mayo, José Manuel (Madrid) Navas Elorza, Enrique (Madrid) Aguado García, José Ma (Madrid) Ena Muñoz, Javier (Alicante) Ortiz de Lejarazu Leona, Raúl (Valladolid) Aguirrebengoa Iranguren, Koldo (Bilbao) Ezpeleta Baquedano, Ma Carmen (Bilbao) Oteo Revuelta, José Antonio (Logroño) Alarcón Cavero, Teresa (Madrid) Falguera Sacrest, Miguel (Lleida) Pachón Díaz, Jerónimo (Sevilla) Alarcón González, Arístides de (Sevilla) Fariñas Álvarez, Carmen (Santander) Pascual Hernández, Alvaro (Madrid) Alcamí Pertejo, José (Madrid) Fernández Guerrero, Manuel Luis (Madrid) Pérez-Cecilia Carrera, Elisa (Madrid) Álvarez Lerma, Francisco (Barcelona) García Riestra, Carlos (Santiago de Pérez Sáenz, José Luis (Palma de Mallorca) Andreu Domingo, Antonia (Barcelona) Compostela) Pérez Trallero, Emilio (San Sebastián) Ariza Cardenal, Javier (Barcelona) García Sánchez, Elías (Salamanca) Picazo de la Garza, Juan José (Madrid) Arrizabalaga Aguirreazaldegui, Julio Gatell Artigas, José Ma (Barcelona) Pigrau Serrallach, Carlos (Barcelona) (San Sebastián) Giménez Pérez, Monserrat (Badalona) Podzamczer Palter, Daniel (Barcelona) Ausina Ruiz, Vicente (Badalona) Gimeno Cardona, Concepción (Valencia) Prieto Prieto, José (Madrid) Azanza Perea, José Ramón (Pamplona) Gómez Gómez, Joaquín (Murcia) Pulido Ortega, Federico (Madrid) Aznar Martín, Javier (Sevilla) Gómez-Garcés, José Luis (Madrid) Pumarola Suñé, Tomás (Barcelona) Baquero Mochales, Fernando (Madrid) González García, Juan (Madrid) Regueiro García, Benito (Santiago de Barberán López, José (Madrid) Guarro Artigas, Josep (Reus) Compostela) Berenguer Berenguer, Juan (Madrid) Gudiol Munté, Francisco (Barcelona) Reina Prieto, Jordi (Palma de Mallorca) Blázquez Gómez, Jesús (Madrid) Guerrero Espejo, Antonio (Valencia) Rello Condomines, Jordi (Tarragona) Bouza Santiago, Emilio (Madrid) Gurgi Ferrer, Merce (Barcelona) Rivero Román, Antonio (Córdoba) Cantón Moreno, Rafael (Madrid) León Gil, Cristóbal (Sevilla) Rodrigo y Gonzalo de Liria, Carlos Capdevila Morell, José A. (Barcelona) Llinares Mondéjar, Pedro (A Coruña) (Badalona) Carratalá Fernández, Jordi (Barcelona) López-Vélez, Rogelio (Madrid) Rodríguez Baño, Jesús (Sevilla) Cartón Sánchez, José Antonio (Oviedo) Lumbreras Bermejo, Carlos (Madrid) Rodríguez Tudela, Juan Luis (Madrid) Casabona Barberá, Jordi (Badalona) Macías Sánchez, Juan (Sevilla) Romero Vivas, José (Madrid) Casal Lombos, Julio (Madrid) Mallolas Masferrer, José (Barcelona) Roselló Urgell, José (Barcelona) Casal Román, Manuel (Córdoba) Marco Reverte, Francesc (Barcelona) Royo García, Gloria (Elche) Caylá Buqueras, Joan (Barcelona) Maroto Vela, Ma Carmen (Granada) Sabriá Leal, Miquel (Barcelona) Salavert Lleti, Miguel (Valencia) Cisneros Herreros, José Miguel (Sevilla) Mensa Pueyo, José (Barcelona) Segovia Hernández, Manuel (Murcia) Cisterna Cáncer, Ramón (Bilbao) Miró Meda, José María (Barcelona) Torres Tortosa, Manuel (Algeciras) Cobo Reinoso, Francisco J. (Madrid) Moreno Camacho, Asunción (Barcelona) Trilla García, Antonio (Barcelona) De Cueto López, Marina (Sevilla) Moreno Guillén, Santiago (Murcia) Vázquez Moreno, Julio (Madrid) De la Torre Cisneros, Julián (Córdoba) Muñoz Bellido, Juan Luis (Salamanca) Vila Estapé, Jordi (Barcelona) Delgado Rubio, Alfonso (Bilbao) Muñoz Sanz, Agustín (Badajoz) Domingo Pedrol, Pere (Barcelona) Navarro Risueño, Ferran (Barcelona) Avda. Josep Tarradellas, 20-30, 1.º de sus titulares, salvo excepción prevista por la ley. Tarifa de suscripción anual IVA incluido Tel. 932 000 711 • 08029 Barcelona Diríjase a CEDRO (CentroEspañol de Derechos On line: 235,02 € Reprográficos, www.cedro.org) si necesita fotocopiar Zurbano, 76 Precios válidos sólo para España Tel. 914 021 212 • 28010 Madrid o escanear algún fragmento de esta obra. Suscripciones y atención al cliente: Publicación mensual (10 números al año) Ni Elsevier ni la Sociedad Española de Elsevier España, S.L.U. Enfermedades Infecciosas y Microbiología Clínica © Copyright 2019 Elsevier España, S.L.U. y Avda. Josep Tarradellas, 20-30, 1º, 08029 Barcelona tendrán responsabilidad alguna por las lesiones y/o Sociedad Española de Enfermedades Infecciosas y Teléfono: daños sobre personas o bienes que sean el resultado 93 241 59 60. Microbiología Clínica. de presuntas declaraciones difamatorias, violaciones Correo electrónico: [email protected] Reservados todos los derechos. El contenido de la de derechos de propiedad intelectual, industrial o presente publicación no puede ser reproducido, ni privacidad, responsabilidad por producto o negli- Contratación de publicidad: transmitido por ningún procedimiento electrónico o gencia. Tampoco asumirán responsabilidad alguna Almudena Álvarez-Cascos mecánico, incluyendo fotocopia, grabación magnéti- por la aplicación o utilización de los métodos, pro- Tel: 91 556 80 25 ca, ni registrado por ningún sistema de recuperación ductos, instrucciones o ideas descritos en el presente Correo electrónico: [email protected] de información, en ninguna forma, ni por ningún material. En particular, se recomienda realizar una Protección de datos: Elsevier España, S.L.U. declara cumplir medio, sin la previa autorización por escrito del titu- verificación independiente de los diagnósticos y de lo dispuesto por la Ley Orgánica 3/2018, de 5 de diciembre, lar de los derechos de explotación de la misma. las dosis farmacológicas. de Protección de Datos Personales y Garantía de los Derechos ELSEVIER ESPAÑA, a los efectos previstos en el Aunque el material publicitario se ajusta a los Digitales (LOPDGDD). artículo 32.1 párrafo segundo del vigente TRLPI, estándares éticos (médicos), su inclusión en esta Miembro de la Asociación de Prensa Profesional. se opone de forma expresa al uso parcial o total publicación no constituye garantía ni refrendo algu- Sección Ciencias de la Salud de las páginas de ENFERMEDADES INFECCIOSAS Y no de la calidad o valor de dicho producto, ni de las Papel ecológico libre de cloro MICROBIOLOGÍA CLÍNICA con el propósito de elaborar afirmaciones realizadas por su fabricante. resúmenes de prensa con fines comerciales. Esta publicación se imprime en papel no ácido Cualquier forma de reproducción, distribución, ENFERMEDADES INFECCIOSAS Y This publication is printed in acid-free paper comunicación pública o transformación de esta MICROBIOLOGÍA CLÍNICA Se distribuye exclusi- Impreso en España. obra sólo puede ser realizada con la autorización vamente entre los profesionales de la medicina Depósito legal: B-40.910-82 • ISSN: 0213-005X XI Congreso Nacional GeSIDA y XIII Reunión Docente de la Red de Investigación de Sida (RIS) Toledo, 10-13 de diciembre de 2019 Comité de Honor Excma. Sra. D.ª María Luisa Carcedo Roces Ministra de Sanidad, Consumo y Bienestar Social Excmo. Sr. D. Emiliano García-Page Sánchez Presidente de la Junta de Comunidades de Castilla-La Mancha Excmo. Sr. D. Jesús Fernández Sanz Consejero de Sanidad de Castilla-La Mancha Excma. Sra. D.ª Milagros Tolón Jaime Alcaldesa de Toledo D.ª Pilar Aparicio Azcárraga Directora General de Salud Pública, Calidad e Innovación D.ª Julia del Amo Valero Secretaria del Plan Nacional sobre el SIDA D. Jordi Vila Estapé Presidente Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica-SEIMC Comité Organizador Presidentes José López Aldeguer José Antonio Pérez Molina Fernando Lozano Juan Berenguer Ana Isabel Mariño Esteban Martínez Miembros Javier Martínez-Picado José Alcamí José M.ª Miró José Ramón Blanco M.ª Luisa Montes Javier de la Torre Santiago Moreno Rafael Delgado Montserrat Plana Pere Domingo Eva Poveda Federico García Federico Pulido Juan González Antonio Rivero Félix Gutiérrez Rafael Rubio África Holguín Isabel Viciana José Antonio Iribarren Eloísa Yuste 01_COMITE_GESIDA 2019.indd 1 20/11/19 11:16 Comité Científico Antonio Antela M.ª Angeles Muñoz José Ramón Arribas M.ª Luisa Navarro Julià Blanco Rosario Palacios M.ª José Buzón Daniel Podzamczer María Teresa Coiras Luis Miguel Real Fernando Cuadra Ezequiel Ruiz-Mateos Carmen Hidalgo Tenorio Pablo Ryan Arkaitz Imaz Matilde Sánchez Conde Inmaculada Jarrín Sergio Serrano Juan Carlos López Bernaldo de Quirós Inés Suárez Mar Masiá Miguel Torralba Marta Massanella Françesc Vidal Coordinadores de la RIS José Alcamí Santiago Moreno Comité Ejecutivo de la RIS José Alcamí María Angeles Muñoz David Dalmau Javier Martínez Picado Felipe García Santiago Moreno Juan González Daniel Podzamczer Félix Gutiérrez Antonio Rivero Inmaculada Jarrín Ezequiel Ruiz Mateos 01_COMITE_GESIDA 2019.indd
Load more

Recommended publications
  • Merck & Co., Inc
    As filed with the Securities and Exchange Commission on February 25, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 _________________________________ FORM 10-K (MARK ONE) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2020 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 1-6571 _________________________________ Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth New Jersey 07033 (908) 740-4000 New Jersey 22-1918501 (State or other jurisdiction of incorporation) (I.R.S Employer Identification No.) Securities Registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock ($0.50 par value) MRK New York Stock Exchange 1.125% Notes due 2021 MRK/21 New York Stock Exchange 0.500% Notes due 2024 MRK 24 New York Stock Exchange 1.875% Notes due 2026 MRK/26 New York Stock Exchange 2.500% Notes due 2034 MRK/34 New York Stock Exchange 1.375% Notes due 2036 MRK 36A New York Stock Exchange Number of shares of Common Stock ($0.50 par value) outstanding as of January 31, 2021: 2,530,315,668. Aggregate market value of Common Stock ($0.50 par value) held by non-affiliates on June 30, 2020 based on closing price on June 30, 2020: $195,461,000,000. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • (51) International Patent Classification: Declarations Under Rule 4.17
    ) ( (51) International Patent Classification: Declarations under Rule 4.17: A61K9/00 (2006.01) A61K 31/675 (2006.01) — as to applicant's entitlement to apply for and be granted a A61K9/14 (2006.01) A61K 31/683 (2006.01) patent (Rule 4.17(H)) A61K9/16 (2006.01) — as to the applicant's entitlement to claim the priority of the (21) International Application Number: earlier application (Rule 4.17(iii)) PCT/US2020/046758 Published: (22) International Filing Date: — with international search report (Art. 21(3)) 18 August 2020 (18.08.2020) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/888,959 19 August 2019 (19.08.2019) US (71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333 Lakeside Drive, Foster City, California 94404 (US). (72) Inventors: BANE, Jessica M.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). NEJATI, Elham; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). STEFANIDIS, Dimitrios; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). (74) Agent: BAJPAI, Reena et al.; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
    [Show full text]
  • What's New in Hiv? Highlights & New Data on Hiv Treatment a Presentation for Healthtrust Members June 18, 2021
    WHAT'S NEW IN HIV? HIGHLIGHTS & NEW DATA ON HIV TREATMENT A PRESENTATION FOR HEALTHTRUST MEMBERS JUNE 18, 2021 SHIVANI PATEL, PHARMD PGY-1 PHARMACY RESIDENT ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL NAVANEETH NARAYANAN, PHARMD, MPH, BCIDP CLINICAL ASSOCIATE PROFESSOR RUTGERS UNIVERSITY ERNEST MARIO SCHOOL OF PHARMACY CONFLICT OF INTEREST DISCLOSURE There are no relevant financial interest to disclose for myself or my spouse/partner within the last 12 months. The preceptor has a financial interest/arrangement, affiliation or relationship with Astellas and Merck that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. Note: This program may contain the mention of suppliers, brand products, services, or drugs presented in a case study or comparative format using evidence-based research. Such examples are intended for educational and informational purposes only and should not be perceived as an endorsement of any particular supplier, brand, product, service or drug. 1 2 3 LEARNING Identify new antiretroviral Describe a two-drug regimen Outline key counseling points agents and their role in the for treatment-naïve to a patient receiving new OBJECTIVES management of HIV/AIDS individuals and factors to antiretroviral agents related consider when selecting an to drug administration, initial regimen for an potential side effects, and individual. drug-drug interactions DRUG NAME ABBREVIATIONS Abbreviation Full Name Abbreviation Full Name Abbreviation Full Name 3TC Lamivudine DTG Dolutegravir
    [Show full text]
  • To View the CAHR 2020 Abstract Book
    29th Annual Canadian 29e Congrès annuel Conference on canadien de recherche HIV/AIDS Research sur le VIH/sida Hope, Victories and Perseverance beyond 2020 Hope, Victoires et Persévérance au-delà de 2020 ABSTRACTS ABRÉGÉS www.cahr-acrv.ca CAHR 2020 VIRTUAL CAHR 2020 Hope, Victories and Perseverance beyond 2020 ACRV 2020 Espoir, Victoires et Persévérance au-delà de 2020 Abstracts / Abrégés May 1 - 2, 2020 / 1 au 2 mai 2020 Virtual Conference Due to COVID-19, the 29th Annual Canadian Conference on HIV/AIDS Research -- which was scheduled to take place in Quebec City -- became CAHR 2020 Virtual. This compendium of abstracts represents those that were approved for the face to face program as developed by the 2020 Conference Scientific Committee. The 29th Annual Canadian Conference on HIV/AIDS Research April 2020 29e Congrès annuel canadien de recherche sur le VIH/sida avril 2020 CAHR Committees / Comités de l’ACRV CAHR Executive Committee / Conseil de direction de l’ACRV President / Président Dr. Carol Strike President Elect / Président désigné Dr. Keith Fowke Past President / Ancien président Dr. Curtis Cooper Treasurer / Trésorière Dr. Marissa Becker Secretary / Secrétaire Dr. Shariq Haider CAHR Board of Directors / Conseil d’administration de l’ACRV Track A: Basic Sciences / Volet A : Sciences fondamentales Dr. Lyle McKinnon Track B: Clinical Sciences / Volet B : Sciences cliniques Dr. Alexandra King Track C: Epidemiology and Public Health Sciences / Volet C : Épidémiologie et sciences de la santé publique Dr. Angela Kaida Track D: Social Sciences / Volet D : Sciences sociales Dr. Ciann Wilson Community Representative / Représentant communautaire Kerrigan Johnson CAHR Staff Members / Personnel de l’ACRV Executive Director / Directeur général Andrew Matejcic Sponsorship, Accreditation, Education Erin Love Gestionnaire, Commandites, agrément et formation Finance, Communications Shelley Mineault Gestionnaire Finances et communications Scientific Program Committee / Comité du programme scientifique Conference Co-Chairs / Coprésidents du congrès Dr.
    [Show full text]
  • Guidelines for the Use of Antiretroviral Agents in Adults and Adolescent Living With
    Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC) How to Cite the Adult and Adolescent Guidelines: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/ AdultandAdolescentGL.pdf. Accessed [insert date] [insert page number, table number, etc. if applicable] It is emphasized that concepts relevant to HIV management evolve rapidly. The Panel has a mechanism to update recommendations on a regular basis, and the most recent information is available on the HIVinfo Web site (http://hivinfo.nih.gov). What’s New in the Guidelines? August 16, 2021 Hepatitis C Virus/HIV Coinfection • Table 18 of this section has been updated to include recommendations regarding concomitant use of fostemsavir or long acting cabotegravir plus rilpivirine with different hepatitis C treatment regimens. June 3, 2021 What to Start • Since the release of the last guidelines, updated data from the Botswana Tsepamo study have shown that the prevalence of neural tube defects (NTD) associated with dolutegravir (DTG) use during conception is much lower than previously reported. Based on these new data, the Panel now recommends that a DTG-based regimen can be prescribed for most people with HIV who are of childbearing potential. Before initiating a DTG-based regimen, clinicians should discuss the risks and benefits of using DTG with persons of childbearing potential, to allow them to make an informed decision.
    [Show full text]
  • Prep and Microbicides PIPELINE REPORT 2021
    Pipeline Report » 2021 PrEP and Microbicides PIPELINE REPORT 2021 The PrEP and Microbicides Pipeline By Richard Jefferys The scientific development of medical interventions can sometimes become fixated on potential one-size-fits-all “home run” solutions. In the realm of biomedical HIV prevention research, community advocates have helped push back against this model, emphasizing the critical importance of creating an array of effective options that people can choose based on their individual situation. The PrEP and microbicide pipelines reflect the pursuit of diverse approaches, including oral, injectable, and topical candidates. Despite the COVID-19 pandemic, 2020 was a year of exceptional progress in HIV prevention research. The most significant news in microbicide development is that, in July 2020, the dapivirine vaginal ring received a positive opinion from the European Medicines Agency (EMA) for use by cisgender women aged 18 and over in high-burden developing countries “when oral pre-exposure prophylaxis (PrEP) is not used, cannot be used or is not available.” This was followed by the addition of the dapivirine vaginal ring to the World Health Organization (WHO) list of prequalified medicines, and in January 2021, the WHO issued a recommendation for the ring as “a new choice for HIV prevention for women at substantial risk of HIV infection.” The International Partnership for Microbicides (IPM) is now seeking regulatory approval for the ring in Kenya, Malawi, Rwanda, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe. For Eswatini and Lesotho, IPM is taking steps to make the ring available under national import license processes. An application to the U.S. Food and Drug Administration (FDA) was submitted in December 2020.
    [Show full text]
  • Merck Announces Week 96 Data from Phase 2B Study Evaluating Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
    NEWS RELEASE Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination With Doravirine in Adults With HIV-1 Infection 10/8/2020 Treatment With Islatravir and Doravirine Maintained Viral Suppression and No Viral Resistance was Identied Company Also Presenting Phase 1/1b Results for MK-8507, a New Investigational Once- Weekly Oral HIV Agent; Company Advances MK-8507 to Phase 2 KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced Week 96 data from the Phase 2b trial (NCT03272347) evaluating the ecacy and safety of islatravir, the company’s investigational oral nucleoside reverse transcriptase translocation inhibitor (NRTTI), in combination with doravirine (PIFELTRO™), in treatment-naïve adults with HIV-1 infection. Week 96 ndings demonstrated that the combination of islatravir and doravirine maintained virologic suppression (as measured by the number of study participants achieving HIV-1 RNA levels <50 copies/mL, similar to DELSTRIGO™(doravirine/lamivudine/tenofovir disoproxil fumarate)), and the ndings were consistent with Week 48 results. Additional Week 96 data from the study show low rates of participants meeting the denition of protocol- dened virologic failure (PDVF) in both the islatravir plus doravirine and the DELSTRIGO treatment arms, and no participants in either arm met the criteria for resistance testing. Merck also announced results from Phase 1/1b studies for MK-8507, the company’s investigational once-weekly oral non-nucleoside reverse transcriptase inhibitor (NNRTI), which showed that the antiviral potency and pharmacokinetics of MK-8507 support further investigation for once-weekly oral administration as part of combination antiretroviral therapy.
    [Show full text]
  • Antiretroviral Drugs Impact Autophagy with Toxic Outcomes
    cells Review Antiretroviral Drugs Impact Autophagy with Toxic Outcomes Laura Cheney 1,*, John M. Barbaro 2 and Joan W. Berman 2,3 1 Division of Infectious Diseases, Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA 2 Department of Pathology, Montefiore Medical Center and Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA; [email protected] (J.M.B.); [email protected] (J.W.B.) 3 Department of Microbiology and Immunology, Montefiore Medical Center and Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA * Correspondence: [email protected]; Tel.: +1-718-904-2587 Abstract: Antiretroviral drugs have dramatically improved the morbidity and mortality of peo- ple living with HIV (PLWH). While current antiretroviral therapy (ART) regimens are generally well-tolerated, risks for side effects and toxicity remain as PLWH must take life-long medications. Antiretroviral drugs impact autophagy, an intracellular proteolytic process that eliminates debris and foreign material, provides nutrients for metabolism, and performs quality control to maintain cell homeostasis. Toxicity and adverse events associated with antiretrovirals may be due, in part, to their impacts on autophagy. A more complete understanding of the effects on autophagy is essential for developing antiretroviral drugs with decreased off target effects, meaning those unrelated to viral suppression, to minimize toxicity for PLWH. This review summarizes the findings and highlights the gaps in our knowledge of the impacts of antiretroviral drugs on autophagy. Keywords: HIV; antiretroviral drugs; side effects; toxicity; autophagy; mitophagy; mitochondria; Citation: Cheney, L.; Barbaro, J.M.; ER stress Berman, J.W.
    [Show full text]
  • Prioritisation of Hiv, Hepatitis C and Tuberculosis Medicines for In-Licensing by the Medicines Patent Pool - 2019 Table of Contents
    PRIORITISATION OF HIV, HEPATITIS C AND TUBERCULOSIS MEDICINES FOR IN-LICENSING BY THE MEDICINES PATENT POOL - 2019 TABLE OF CONTENTS 1. Introduction 4 2. Priorities in HIV 5 3. Priorities in Hepatitis C 8 4. Priorities in Tuberculosis 8 3 AKNOWLEDGEMENTS The MPP is grateful to the experts participating in various meetings including the WHO Think Tank, the Paediatric Antiretroviral Drug Optimization (PADO), the Workshop of the Long-Acting/Extended Release Antiretroviral Resource Program (LEAP) and the Conference on Retroviruses and Opportunistic Infections (CROI) whose contributions and insights contributed to the updating of the MPP prioritisation. Discussions over the past year with a wide range of experts in academic and civil society organizations were also extremely helpful to further understand the potential of different medicines. The final assessment, however, is the responsibility of the MPP alone. 4 1. INTRODUCTION The first step in MPP’s work on licensing of HIV, hepatitis C and tuberculosis medicines is selecting possible candidate medicines for in-licensing. This selection is done on an annual basis applying a prioritisation methodology that was developed in 2016 in the context of the MPP’s second grant with Unitaid, and further refined in 2017 and 2018. The objective of the prioritisation is to select candidate medicines for in-licensing that could have the greatest impact for public health in low- and middle-income countries (LMICs). The methodology relies on a thorough review of the medicines on the market as well as those in late-stage development, and consists in an analysis of available clinical data on each medicine, scope and breadth of patent protection, licensing status and market potential.
    [Show full text]
  • Download the Article On
    CHILDREN AND THE ‘BIG THREE’ EPIDEMICS Despite significant advances in HIV, many children remain at risk JUNE This article is one of a series of three. It dives into the current situa- tion for HIV, highlighting the speci c burden on children, setting out what needs to happen next in terms of product development and the remaining product gaps. It underscores the need for a diverse range of new treatments that are suitable for children, especially with the growing threat of drug resistance. 12 Despite signi cant advances in HIV, many children remain at risk 14 Market insight 16 Research & development insight 18 Ensuring access 19 Case studies: How companies and organisations are working to improve access to paediatric ARVs HIV - CONTEXT Despite significant advances in HIV, many children remain at risk ©Medicines Patent Pool ©Medicines Patent AT A GLANCE Forty years after its outbreak, HIV is one of the ARVs, healthcare providers and caregivers often greatest pandemics of modern times. Great pro- resort to manipulating adult formulations such Resistance to chloroquine in the 1990s was responsiblegress has for almost been made in the prevention and treat- as breaking or crushing pills to approximate the doubling malaria-associated deaths in sub-Saharanment Africa. of the disease, including paediatric HIV and required dose, causing issues related to absorption AIDS. This is thanks in large part to coordinated and increasing the risk of inaccurate dosing. Progress has been and sustained commitment from governments, made NGOs, civil society and industry. Ensuring uninterrupted supply In East and Southern In East and Southern Africa, mother-to-child Weaknesses or distributions in ARV supply chains Africa, mother-to- transmission of HIV has decreased by almost half are also considered driving factors behind the child transmission of since 2010.
    [Show full text]
  • Oral, Parenteral, and Vaginal Dosage Forms for Prevention of HIV/Stis and Unplanned Pregnancy
    polymers Review Multipurpose Prevention Technologies: Oral, Parenteral, and Vaginal Dosage Forms for Prevention of HIV/STIs and Unplanned Pregnancy Isabella C. Young 1 and Soumya Rahima Benhabbour 1,2,* 1 Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 2 Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA * Correspondence: [email protected]; Tel.: +1-(919)-843-6142 Abstract: There is a high global prevalence of HIV, sexually transmitted infections (STIs), and un- planned pregnancies. Current preventative daily oral dosing regimens can be ineffective due to low patient adherence. Sustained release delivery systems in conjunction with multipurpose prevention technologies (MPTs) can reduce high rates of HIV/STIs and unplanned pregnancies in an all-in-one ef- ficacious, acceptable, and easily accessible technology to allow for prolonged release of antivirals and contraceptives. The concept and development of MPTs have greatly progressed over the past decade and demonstrate efficacious technologies that are user-accepted with potentially high adherence. This review gives a comprehensive overview of the latest oral, parenteral, and vaginally delivered MPTs in development as well as drug delivery formulations with the potential to advance as an MPT, and implementation studies regarding MPT user acceptability and adherence. Furthermore, Citation: Young, I.C.; Benhabbour, there is a focus on MPT intravaginal rings emphasizing injection molding and hot-melt extrusion S.R. Multipurpose Prevention manufacturing limitations and emerging fabrication advancements.
    [Show full text]
  • Inhibitors & Agonists Compound Screening Libraries
    www.MedChemExpress.com MedChemExpress Inhibitors & Agonists 25,000+ Specific Inhibitors & Agonists Targeting 20+ Classic Signaling Pathways Compound Screening Libraries 50+ Compound Screening Libraries Optimized for Disease Mechanism Revealing & Drug Repurposing Nature. 2020 Apr;580(7803):386-390. Cell. 2020 Apr 6. pii: S0092-8674(20)30268-3. Cell. 2020 Mar 5;180(5):941-955.e20. Nature. 2020 Mar;579(7799):433-437. Science. 2020 Feb 14;367(6479):806-810. Cell. 2020 Feb 20;180(4):645-654.e13. Nature. 2019 Dec;576(7786):274-280. Cell. 2019 Dec 12;179(7):1483-1498.e22. Cell. 2019 Dec 12;179(7):1566-1581.e16. Nature. 2019 Nov;575(7782):375-379. Nature. 2019 Nov;575(7784):683-687. Nature. 2019 Oct;574(7777):264-267. Cell. 2019 Oct 31;179(4):864-879.e19. Nat Nanotechnol. 2019 Oct;14(10):988-993. Publications Citing Use of MCE Products Citing Use of Publications Nat Biotechnol. 2019 Oct;37(10):1209-1216. Cell. 2019 Aug 22;178(5):1145-1158.e20. Cell. 2019 Aug 22;178(5):1132-1144.e10. Nature. 2019 Jul;571(7763):127-131. Science. 2019 Jul 19;365(6450). Cell. 2019 Jul 25;178(3):585-599.e15. Cell. 2019 Jul 11;178(2):330-345.e22. Inhibitors & Agonists “ 25,000+ selective Inhibitors and Agonists We offer Targeting 375 key proteins in 20+ signaling pathways only the Applications in different disease areas highest- Screening Libraries grade MCE Compound Screening Libraries consist of 10,000+ small molecules with products! validated biological and pharmacological activities Quality Our robust quality control methods assure product high quality and purity.
    [Show full text]